Vir Biotechnology reported a net loss of $213.7 million in Q3 2024, alongside total revenues of $2.4 million and cash reserves of $1.19 billion.

The European Medicines Agency (EMA) has drafted a concept paper outlining considerations for future guidelines on radiopharmaceuticals, addressing the unique aspects of these medicinal products.

SHR-A1921, an antibody-drug conjugate, demonstrated a 42.3% overall response rate in platinum-resistant ovarian cancer patients at a 3.0 mg/kg dose.

The Phase 3 IMforte trial demonstrated that lurbinectedin combined with atezolizumab significantly improved overall survival (OS) and progression-free survival (PFS) in ES-SCLC patients.

Oncodesign Precision Medicine presented Phase 1 clinical trial results for OPM-101, a RIPK2 kinase inhibitor, at UEG Week 2024, showcasing its safety profile.

Immunic's vidofludimus calcium is under investigation in Phase 3 trials for relapsing MS and Phase 2 for progressive MS, targeting both inflammation and neuroprotection.

Cytokinetics submitted a New Drug Application (NDA) to the FDA for aficamten in Q3, marking a significant step toward potential U.S. approval.

A clinical trial reveals that adding nivolumab to chemotherapy before surgery significantly improves outcomes for ER+/HER2- breast cancer patients.

Acrivon Therapeutics has granted equity awards to employees under its 2023 Inducement Plan, consisting of options to purchase 61,950 shares of common stock.

Anavex Life Sciences reports positive preliminary results from its Phase 2 trial of ANAVEX3-71 in schizophrenia, showing dose-dependent effects on EEG biomarkers.

A novel three-drug combination, including inavolisib, has demonstrated a doubling of survival time in patients with advanced breast cancer compared to standard treatments.

Corcept Therapeutics' Phase III GRADIENT trial of relacorilant in Cushing's syndrome did not meet its primary endpoint of statistically significant improvement in systolic blood pressure.

The phase 3 AMPLIFY trial demonstrated that acalabrutinib plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival (PFS) in treatment-naive CLL patients.

Exagamglogene autotemcel (exa-cel) shows promise as a one-time treatment for severe sickle cell disease (SCD), particularly in preventing vaso-occlusive events (VOCs).

BriaCell Therapeutics reported an operating loss of $(5.15) million, alongside a net loss of $(5.83) million, influenced by fair value changes in warrant liability.

The NIHR and SNSF are partnering to provide £8 million in funding for joint Swiss-UK clinical trials focused on areas of unmet need.

The LODEFI phase 2 trial demonstrated that low-dose deferasirox induced transfusion independence in nearly half of patients with low-risk myelodysplastic syndrome (MDS).

Palatin Technologies' Bremelanotide demonstrated positive results in a Phase IIb trial for Type 2 Diabetic Nephropathy, a leading cause of end-stage renal disease.

A phase 2 study reveals that alternating mCAPOX/mCAPIRI plus bevacizumab demonstrates favorable efficacy in previously untreated, unresectable metastatic colorectal cancer (mCRC).

Statistical data monitoring (SDM) significantly improves clinical trial quality by identifying atypical data patterns that may indicate issues in trial conduct.